Barcelona, Spain & London, UK – September 8, 2026 – AstraZeneca has ignited a new era in chronic obstructive pulmonary disease (COPD) treatment with the presentation of groundbreaking Phase III data for its interleukin-33 (IL-33) inhibitor, tozorakimab. Unveiled at the prestigious European Respiratory Society (ERS) Congress in Barcelona and simultaneously published in the esteemed New England Journal of Medicine, these results herald a potential paradigm shift, demonstrating unprecedented efficacy in reducing moderate and severe exacerbations across a broad spectrum of COPD patients, including those historically underserved by existing biologic therapies.
n
The data from the OBERON (NCT05166889) and TITANIA (NCT05158387) trials confirm that tozorakimab met its primary and secondary endpoints, positioning it as potentially the first biologic capable of gaining approval for a wide COPD population regardless of their blood eosinophil counts (BEC) or smoking status. This breakthrough challenges the prevailing notion that biologic success in COPD is confined to specific eosinophil-high subgroups, opening the door to more inclusive and effective therapeutic strategies for millions suffering from this debilitating lung condition.
n
Understanding the Unmet Need in COPD
n
Chronic obstructive pulmonary disease affects hundreds of millions globally, ranking as a leading cause of morbidity and mortality. Characterized by persistent respiratory symptoms and airflow limitation, COPD often progresses to severe exacerbations—acute worsenings of symptoms that frequently lead to hospitalizations, accelerated lung function decline, and increased mortality risk. While inhaled bronchodilators and corticosteroids form the backbone of standard-of-care therapy, a significant proportion of patients continue to experience recurrent exacerbations, highlighting a critical unmet medical need.
n
For years, the development of targeted biologic therapies for COPD has largely mirrored the success seen in asthma, focusing on Type 2 inflammatory pathways, particularly those driven by high eosinophil counts. Biologics like dupilumab (targeting IL-4/IL-13) and mepolizumab (targeting IL-5) have shown benefit, but their use is typically restricted to patients with moderate-to-severe COPD who exhibit elevated blood eosinophil levels (e.g., ≥300 cells/µL). This leaves a vast patient population—including those with low eosinophil counts (often <150 cells/µL) and active smokers—without effective biologic options, perpetuating a significant treatment gap. The inability to address exacerbations in these broad patient groups has been a major challenge, contributing to the persistent burden of COPD.
n
The OBERON and TITANIA Trials: A Deep Dive into Design and Data
n
The OBERON and TITANIA trials were meticulously designed to evaluate tozorakimab’s efficacy and safety in a real-world, broad COPD population. These were double-blind, placebo-controlled Phase III studies, collectively enrolling just over 2,300 patients who had a history of significant exacerbation activity—specifically, two or more moderate or one or more severe COPD exacerbations in the 12 months prior to enrollment.
n
Patients in both trials were randomized to receive either tozorakimab 300mg or a placebo every four weeks for a duration of 52 weeks, administered as an add-on therapy to their existing inhaled maintenance regimens. A key differentiator in the trial design was the deliberately wide inclusion criteria. Unlike previous biologic studies that often pre-selected patients based on high eosinophil counts, OBERON and TITANIA enrolled both current and former smoking patients, encompassed all blood eosinophil counts, and included individuals across all stages of lung function severity. This inclusive approach was pivotal, aiming to assess the drug’s potential beyond the narrow eosinophil-high subgroups that have historically defined biologic success in COPD.
n
The primary endpoint for both trials was the annual rate of moderate or severe COPD exacerbations. The results were compelling:
n
- n
- Overall Efficacy: Tozorakimab demonstrated a significant reduction in exacerbation rates.
- Smoking Status Subgroup: Notably, the drug reduced exacerbation rates in former smokers by 29% in the OBERON trial and by 34% in the TITANIA trial compared to placebo. While specific numbers for current smokers weren’t highlighted in the initial summary, the broad inclusion criteria and the subsequent BEC subgroup analysis underscore its potential relevance for this population.
n
n
n
Unprecedented Efficacy Across the Eosinophil Spectrum
n
Perhaps the most consequential finding from the OBERON and TITANIA trials emerged from the subgroup analysis by blood eosinophil count (BEC). This analysis directly addressed the long-standing challenge of treating patients with low eosinophil levels, a population where most biologics in COPD have historically underperformed or shown minimal benefit.
n
The data revealed a robust and consistent reduction in exacerbations across the eosinophil spectrum:
n
- n
- Patients below 150 cells/µL: This traditionally hard-to-treat group experienced a 23% reduction in exacerbations. This figure is particularly significant as it represents a clear clinical benefit in a population previously lacking targeted biologic options.
- Patients at 150 cells/µL or above: The reduction in exacerbations rose to 34%.
- Patients at 300 cells/µL and above: Efficacy was even more pronounced, showing a 43% reduction in exacerbations.
n
n
n
n
These impressive figures were consistent across both current and former smoking patients and observed in both OBERON and TITANIA trials. According to the trials’ chief investigator, this marks a landmark achievement: "This is the first time a COPD biologic has shown efficacy across the entire eosinophil spectrum, including below the 150 thresholds, regardless of smoking status." This statement underscores the profound implications of tozorakimab, suggesting that targeting the IL-33 pathway offers a mechanism of action that is less dependent on eosinophilic inflammation compared to other established biologics.
n
Beyond efficacy, the safety profile of tozorakimab was also encouraging. Safety data indicated that the drug was generally well tolerated across both clinical trials. Severe adverse events leading to treatment discontinuation were infrequent, occurring in 3.1% of patients in the OBERON trial and 3.7% in the TITANIA trial, suggesting a favorable risk-benefit profile.
n
Regulatory Momentum and Market Entry
n
The positive clinical data is being swiftly followed by robust regulatory action. AstraZeneca has confirmed that the U.S. Food and Drug Administration (FDA) has accepted tozorakimab’s Biologics License Application (BLA) under a Priority Review Voucher. This expedited pathway signals the FDA’s recognition of the drug’s potential to address a serious unmet medical need. A Prescription Drug User Fee Act (PDUFA) date is anticipated in Q1 2027, indicating a relatively rapid review timeline compared to standard applications. Concurrently, regulatory review processes are also well underway in both the European Union and China, paving the way for a broad global launch.
n
This accelerated regulatory track provides AstraZeneca with a significant strategic advantage, putting tozorakimab on a faster trajectory than many rival IL-33 inhibitors, such as Roche’s astegolimab (currently in Phase III ARNASA trial; NCT05595642). This early lead is crucial in a competitive market, allowing AstraZeneca to establish its presence and potentially capture a substantial market share ahead of other pipeline candidates.
n
Navigating the Competitive Landscape: A Shifting Paradigm
n
The entry of tozorakimab promises to reshape the competitive landscape of the COPD biologics market, which until now, has been largely dominated by Dupixent (dupilumab) from Sanofi and Regeneron. Dupixent, while highly effective, operates through the narrower IL-4/IL-13 axis, primarily treating uncontrolled COPD patients with Type 2 inflammation, typically defined by a BEC of 300 cells/µL or more. Tozorakimab’s broad efficacy across all severities and, critically, across the entire eosinophil spectrum, positions it as a direct challenger to Dupixent’s market dominance, potentially expanding biologic therapy to a much wider patient population.
n
The IL-33 pathway has been a focal point for several pharmaceutical companies, but AstraZeneca appears to have secured a significant lead. Sanofi’s own IL-33 inhibitor, itepekimab, previously failed to achieve its primary endpoint in its Phase III AERIFY-2 trial (NCT04751487). This setback leaves tozorakimab, for now, as the sole IL-33 asset with positive Phase III data demonstrating efficacy across the broad eosinophil spectrum, solidifying AstraZeneca’s first-mover advantage in this specific mechanism.
n
However, Sanofi is not without formidable countermeasures. The company is actively advancing its novel bispecific nanobody, lunsekimig, which targets both thymic stromal lymphopoietin (TSLP) and IL-13. Lunsekimig has already reported strong results from its Phase IIb (NCT06102005) in asthma at ERS 2026, and a Phase IIb/III trial (NCT07190209) for COPD is currently underway. TSLP is a crucial upstream cytokine involved in multiple inflammatory pathways, and a bispecific approach could offer broad efficacy that might also transcend eosinophil-dependent mechanisms. Sanofi’s investment in lunsekimig demonstrates a clear intent to defend and potentially expand its position in the respiratory biologics space, even if AstraZeneca establishes an early lead in the broader COPD population with tozorakimab.
Further intensifying market competition is GSK’s entry into the COPD biologics arena. Its IL-5-targeting drug, Nucala (mepolizumab), received FDA approval in Q2 2025 and EMA approval in Q1 2026. While Nucala provides another important option, similar to Dupixent, it is indicated only for moderate-to-severe COPD with an eosinophilic phenotype. This distinction further underscores the groundbreaking broad efficacy of tozorakimab, which targets a patient segment currently unaddressed by Nucala or Dupixent. The different mechanisms of action (IL-33, IL-4/IL-13, IL-5, TSLP) suggest a future where personalized medicine, guided by specific inflammatory biomarkers beyond just eosinophils, will become increasingly vital in selecting the most appropriate biologic for each COPD patient.
Broader Implications for COPD Treatment and Patient Care
The OBERON and TITANIA results represent a transformative moment for the biologic treatment of COPD. By demonstrating clinically meaningful benefit across the entire eosinophil spectrum, including traditionally hard-to-treat, low-eosinophil and current-smoker populations, tozorakimab fundamentally challenges the long-held assumption that COPD biologics must be eosinophil-restricted to be effective. This broad applicability means that a significantly larger proportion of COPD patients who continue to suffer from exacerbations despite optimal inhaled therapy may now have access to a targeted biologic.
The implications for clinical practice are profound. Physicians may no longer need to rely solely on eosinophil counts to identify candidates for biologic therapy, simplifying treatment algorithms and potentially leading to earlier intervention for a broader group of patients. This could translate into improved quality of life, reduced exacerbation rates, fewer hospitalizations, and a slower decline in lung function for millions globally. Combined with its favorable tolerability profile and Priority Review status, tozorakimab is exceptionally well-positioned to become the first biologic approved for a broad COPD population, moving beyond the narrower severe segments currently served by Dupixent and Nucala.
However, the ultimate commercial and clinical impact of tozorakimab will depend on several factors beyond the initial 52-week trial window. These include how convincingly these Phase III results translate into regulatory approval across key markets, the speed and extent of physician adoption, and the demonstration of durable outcomes and long-term safety beyond the trial period. The evolving competitive landscape, with Sanofi’s lunsekimig also advancing with a novel mechanism of action, suggests a dynamic market where continuous innovation will be key.
Market Outlook and Future Projections
The market for COPD therapies is poised for substantial growth, driven by an aging global population, continued prevalence of risk factors, and the introduction of advanced, targeted treatments. GlobalData’s comprehensive COPD Market Drug Forecast projects the COPD market to grow to over $30 billion across the seven major markets (U.S., France, Germany, Spain, Italy, U.K., and Japan) by 2034. Within this expanding market, Dupixent, Nucala, and tozorakimab are expected to emerge as the leading players, each carving out a significant share based on their unique mechanisms and target patient populations.
AstraZeneca’s tozorakimab, with its broad efficacy and first-in-class potential for a widespread COPD population, is set to be a cornerstone of this future growth. Its success would not only solidify AstraZeneca’s position as a leader in respiratory medicine but also mark a pivotal moment for COPD patients worldwide, offering hope for a more inclusive and effective approach to managing this complex and devastating disease. The coming years will undoubtedly witness intense competition and further innovation, ultimately benefiting patients with a wider array of advanced treatment options.
